Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it will present new data from its ALN-TTR program at the VIIIth International Symposium on Familial Amyloidotic Polyneuropathy being held in Kumamoto, Japan from November 20-22, 2011.

15 Nov 2011

New stem cell technique hopes to replace damaged cells in Parkinson's

Australian scientists have developed a new technique using stem cells, in the hope to replace damaged cells in Parkinson's disease. The technique could be developed for application in other degenerative conditions.

13 Nov 2011

Damaged mitochondria equivalent to an environmental disaster in the cell

Current thinking about Parkinson's disease is that it's a disorder of mitochondria, the energy-producing organelles inside cells, causing neurons in the brain's substantia nigra to die or become impaired.

11 Nov 2011

Researchers discover key mechanism responsible for degrading ubiquitinated protein aggregates

Researchers at the RIKEN Brain Science Institute (BSI) have discovered a key mechanism responsible for selectively degrading aggregates of ubiquitinated proteins from the cell.

7 Nov 2011

Scientists identify mechanism by which GBM promotes neurodegeneration

Researchers from Virginia Commonwealth University Massey Cancer Center and the VCU Institute of Molecular Medicine have discovered a mechanism by which glioblastoma multiforme (GBM), the most common form of brain cancer, promotes the loss of function or death of neurons, a process known as neurodegeneration.

4 Nov 2011

GSK, Alnylam collaborate to apply VaxiRNA technology for influenza vaccine production

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it has formed a collaboration with GlaxoSmithKline (GSK) focused on Alnylam's VaxiRNATM technology for certain GSK vaccine products, including influenza. VaxiRNA is a new RNAi technology for the enhanced production of viruses used in the manufacture of vaccine products. GSK, a leading vaccine manufacturer, is the first company to form a collaboration accessing this new platform.

2 Nov 2011

Scientists discover how toxic form of htt protein causes Huntington's symptoms

Scientists at the Gladstone Institutes have discovered how a form of the protein linked to Huntington's disease influences the timing and severity of its symptoms, offering new avenues for treating not only this disease, but also a variety of similar conditions.

31 Oct 2011

FDA approves intraspinal injections in spinal cord stem cell ALS trial

Neuralstem, Inc. updated the progress of its ongoing Phase I safety trial of the company's spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

24 Oct 2011

Johns Hopkins Brain Science Institute organizes Drug Discovery in Academia symposium

A symposium to be hosted by the Johns Hopkins Brain Science Institute (BSi) on Oct. 18 at the Baltimore Convention Center will bring together the pharmaceutical industry and academic-based research institutions with the common goal of exploring how the two can best work together to enhance and facilitate the discovery of new drugs.

15 Oct 2011

Normal Htt protein regulates formation of cellular structures in mouse model of HD

Huntington disease is a devastating neurogenerative disorder that causes a progressive loss of functional capacity and reduced life span. It is an inherited condition caused by a mutant HTT gene. Although this has been known for many years, the functions of the normal Htt protein and the mechanisms by which the mutant protein generated from the mutant HTT gene causes disease are not well understood.

11 Oct 2011

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated dosing in its Phase I clinical trial with ALN-PCS, an RNAi therapeutic targeting proprotein convertase subtilisin/kexin type 9, or PCSK9, for the treatment of severe hypercholesterolemia.

27 Sep 2011

Cedars-Sinai inaugurates new facility to generate induced pluripotent stem cells

The Cedars-Sinai Regenerative Medicine Institute has opened a new Induced Pluripotent Stem Cell (iPSC) Core Facility to produce powerful cells capable of making all tissues of the body from adult human skin cells.

23 Sep 2011

International patient groups anxiously await start of Huntington’s trial

Prana Biotechnology Limited received a very positive reaction from international patient groups and researchers at this week’s World Congress on Huntington’s Disease in Melbourne. The company had a major presence at the Congress and the Prana team has held numerous meetings and conversations with patient groups and researchers.

15 Sep 2011

Clinical trial planned in Australia and the USA to help patients with ‘orphan’ disease

Prana Biotechnology Limited announced today that researchers are planning recruitment for a phase II clinical trial of the experimental drug PBT2 in Huntington’s patients. There are currently no treatments for the genetic, neurodegenerative disease; Australia is increasingly seen as a leader in the development of therapies for neurologic disorders. Huntington’s often affects young adults and progressively impacts the body, mind and emotions. The disease causes incapacitation and death about 15-25 years after onset.

12 Sep 2011

University of Adelaide research focuses on techniques to treat swallowing disorders

A simple function that most of us take for granted - swallowing - is the focus of University of Adelaide research which could help thousands of stroke sufferers around the world.

12 Sep 2011

New treatment strategy for dominant forms of muscular dystrophy

Investigators at The Research Institute at Nationwide Children's Hospital are studying a potential new treatment strategy for dominant forms of muscular dystrophy, thanks to preliminary funding from The Ohio State University Center for Clinical and Translational Science.

12 Sep 2011

Scientist identifies how lack of dopamine leads to symptoms of Parkinson's

A scientist at the Gladstone Institutes has identified how the lack of a brain chemical known as dopamine can rewire the interaction between two groups of brain cells and lead to symptoms of Parkinson's disease.

8 Sep 2011

CIRM approves stem cell research planning grants for five UC Davis teams

The California Institute for Regenerative Medicine (CIRM), the state stem cell agency, today approved research planning grants for five UC Davis Health System teams that are working to develop human clinical trials to treat illnesses such as Huntington's disease, vascular disease, osteoporosis, HIV/AIDS and airway disease in children.

29 Aug 2011

MR spectroscopy reveals biochemical changes in brains of people at risk for Alzheimer's

A brain imaging scan identifies biochemical changes in the brains of normal people who might be at risk for Alzheimer's disease, according to research published in the August 24, 2011, online issue of Neurology-, the medical journal of the American Academy of Neurology.

25 Aug 2011

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the first half year of 2011.

25 Aug 2011

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

New stem cell technique hopes to replace damaged cells in Parkinson's

Damaged mitochondria equivalent to an environmental disaster in the cell

Researchers discover key mechanism responsible for degrading ubiquitinated protein aggregates

Scientists identify mechanism by which GBM promotes neurodegeneration

GSK, Alnylam collaborate to apply VaxiRNA technology for influenza vaccine production

Scientists discover how toxic form of htt protein causes Huntington's symptoms

FDA approves intraspinal injections in spinal cord stem cell ALS trial

Johns Hopkins Brain Science Institute organizes Drug Discovery in Academia symposium

Normal Htt protein regulates formation of cellular structures in mouse model of HD

Alnylam commences ALN-PCS Phase I trial in severe hypercholesterolemia

Cedars-Sinai inaugurates new facility to generate induced pluripotent stem cells

International patient groups anxiously await start of Huntington’s trial

Clinical trial planned in Australia and the USA to help patients with ‘orphan’ disease

University of Adelaide research focuses on techniques to treat swallowing disorders

New treatment strategy for dominant forms of muscular dystrophy

Scientist identifies how lack of dopamine leads to symptoms of Parkinson's

CIRM approves stem cell research planning grants for five UC Davis teams

MR spectroscopy reveals biochemical changes in brains of people at risk for Alzheimer's

AMT total net loss decreases 7% to € 8.7 million for first half year of 2011

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in